Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 1, 2007, Pages 31-39

  Yamazaki, A ^a   Kumagai, Y ^b   Fujita, T ^b   Hasunuma, T ^c   Yokota, S ^b   Maeda, M ^b   Otani, Y ^b   Majima, M ^a  

^a KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c KITASATO INSTITUTE   (Japan)

Author keywords

Benzodiazepine; Food drug interactions; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIAZEPAM; NITRAZEPAM; QUAZEPAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SINGLE DRUG DOSE; SPECTROPHOTOMETRY; VISUAL ANALOG SCALE;

ADULT; AREA UNDER CURVE; BENZODIAZEPINES; BIOLOGICAL AVAILABILITY; DIAZEPAM; FOOD-DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; NITRAZEPAM; PSYCHOMOTOR PERFORMANCE;

EID: 33846794834     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00795.x     Document Type: Article

References (24)

1. Fleisher D, Li C, Zhou Y et al. (1999) Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clinical Pharmacokinetics, 36, 233-254.
2. Singh BN (1999) Effects of food on clinical pharmacokinetics. Clinical Pharmacokinetics, 37, 213-255.
3. Mendels J (1991) Criteria for selection of appropriate benzodiazepine hypnotic therapy. Journal of Clinical Psychiatry, 52(Suppl.), 42-46.
4. Yasui-Furukori N, Takahata T, Kondo T et al. (2003) Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. British Journal of Clinical Pharmacology, 55, 382-388.
5. Doose DR, Minn FL, Stellar S et al. (1992) Effects of meals and meal composition on the bioavailability of fenretinide. Journal of Clinical Pharmacology, 32, 1089-1095.
6. Yasui-Furukori N, Kondo T, Takahata T et al. (2002) Effect of dietary fat content in meals on pharmacokinetics of quazepam. Journal of Clinical Pharmacology, 42, 1335-1340.
7. Kim Y, Morikawa M, Ohsawa H et al. (2003) Effects of foods on the pharmacokinetics and clinical efficacy of quazepam. Nihon Shinkei Seishin Yakurigaku Zasshi, 23, 205-210.
8. Greenblatt DJ, Allen MD, MacLaughlin DS et al. (1978) Diazepam absorption: effect of antacids and food. Clinical Pharmacology and Therapeutics, 24, 600-609.
9. Norris H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology, 10, 181-191.
10. Bond A, Lader M (1974) The use of analogue scales in rating subjective feeling. British Journal of Medical Psychology, 47, 211-218.
11. FDA (1992) FDA guidelines. Rockville, MD: Bioequivalence Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs. 1 July.
12. Roberts RJ, Leff RD (1989) Influence of absorbable and nonabsorbable lipids and lipidlike substances on drug bioavailability. Clinical Pharmacology and Therapeutics, 45, 299-304.
13. 14C-quazepam in man. Drug Metabolism and Disposition, 13, 25-29.
14. Fukasawa T, Yasui-Furukori N, Aoshima T et al. (2004) Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity. Therapeutic Drug Monitoring, 26, 529-533.
15. Schwartz MA, Koechlin BA, Postma E et al. (1965) Metabolism of diazepam in rat, dog, and man. Journal of Pharmacology and Experimental Therapeutics, 149, 423-435.
16. De Morais SM, Wilkinson GR, Blaisdell J et al. (1994) Identification of a new genetic defect responsible for the olymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594-598.
17. Bertilsson L, Henthorn TK, Sanz E et al. (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 45, 348-355.
18. Dasberg HH (1975) Effects and plasma levels of N-desmethyldiazepam after oral administration in normal volunteers. Psychopharmacologia, 43, 191-198.
19. Sawada H, Shinoara K (1971) On the urinary excretion of nitrazepam and its metabolites. Archiv für Toxikologie, 28, 214-221.
20. Rieder J (1973) Plasma levels and derived pharmacokinetic characteristics of unchanged nitrazepam in man. Arzneimittel-Forschung, 23, 212-218.
21. Sieghart W (1983) Several new benzodiazepines selectively interact with a benzodiazepine receptor subtype. Neuroscience Letters, 38, 73-78.
22. Hilbert JM, Iorio L, Moritzen V et al. (1986) Relationships of brain and plasma levels of quazepam, flurazepam, and their metabolites with pharmacological activity in mice. Life Sciences, 39, 161-168.
23. Luurila H, Olkkola KT, Neuvonen PJ (1995) Interaction between erythromycin and nitrazepam in healthy volunteers. Pharmacology and Toxicology, 76, 255-258.
24. Greenblatt DJ, Ehrenberg BL, Gunderman J et al. (1989) Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. Journal of Pharmacology and Experimental Therapeutics, 250, 134-140.